FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2357020384> ?p ?o ?g. }

• W2357020384 endingPage "1033" @default.
• W2357020384 startingPage "1024" @default.
• W2357020384 abstract "OBJECTIVES To determine the proportion of prostate cancer (PCa) patients with oligometastatic disease (≤3 synchronous lesions) using whole body magnetic resonance imaging with diffusion‐weighted imaging (WB‐MRI/DWI). To determine the proportion of patients with nodal disease confined within currently accepted target areas for extended lymph node dissection (eLND) and pelvic external beam radiation therapy (EBRT). SUBJECTS AND METHODS Two radiologists reviewed WB‐MRI/DWI studies in 96 consecutive newly diagnosed metastatic PCa patients; 46 patients with newly diagnosed castration naive PCa (mHNPC) and 50 patients with first appearance of metastasis during monitoring for non‐metastatic castration resistant PCa (M0 to mCRPC). The distribution of metastatic deposits was assessed and the proportions of patients with oligometastatic disease and with LN metastases located within eLND and EBRT targets were determined. RESULTS Twenty‐eight percent of mHNPC and 50% of mCPRC entered the metastatic disease with ≤3 sites. Bone metastases (BM) were identified in 68.8% patients; 71.7% of mHNPC and 66% mCRPC patients. Most commonly involved areas were iliac bones and lumbar spine. Enlarged lymph nodes (LN) were detected in 68.7% of patients; 69.6% of mHNPC and 68.0% of mCRPC. Most commonly involved areas were para‐aortic, inter‐aortico‐cava, and external iliac areas. BM and LN were detected concomitantly in 41% of mHNPC and 34% of mCRPC. Visceral metastases were detected in 6.7%. Metastatic disease was confined to LN located within the accepted boundaries of eLND or pelvic EBRT target areas in only ≤25% and ≤30% of patients, respectively. CONCLUSIONS Non‐invasive mapping of metastatic landing sites in PCa using WB‐MRI/DWI shows that 28% of the mHNPC patients, and 52% of the mCRPC can be classified as oligometastatic, thus challenging the concept of metastatic targeted therapy. More than two thirds of metastatic patients have LN located outside the usually recommended targets of eLND and pelvic EBRT. Prophylactic or salvage treatments of these sole areas in patients with high‐risk prostate cancer may not prevent the emergence of subsequent metastases. Prostate 76:1024–1033, 2016 . © 2016 Wiley Periodicals, Inc." @default.
• W2357020384 created "2016-06-24" @default.
• W2357020384 creator A5019946418 @default.
• W2357020384 creator A5020692060 @default.
• W2357020384 creator A5038994606 @default.
• W2357020384 creator A5043512230 @default.
• W2357020384 creator A5058385398 @default.
• W2357020384 creator A5069112511 @default.
• W2357020384 creator A5077482056 @default.
• W2357020384 creator A5089478129 @default.
• W2357020384 date "2016-05-16" @default.
• W2357020384 modified "2023-10-07" @default.
• W2357020384 title "Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease" @default.
• W2357020384 cites W1965408806 @default.
• W2357020384 cites W1971834606 @default.
• W2357020384 cites W1977265573 @default.
• W2357020384 cites W1979133838 @default.
• W2357020384 cites W1980053751 @default.
• W2357020384 cites W1995497262 @default.
• W2357020384 cites W1996464308 @default.
• W2357020384 cites W2000853346 @default.
• W2357020384 cites W2010227770 @default.
• W2357020384 cites W2014999922 @default.
• W2357020384 cites W2024821597 @default.
• W2357020384 cites W2028722098 @default.
• W2357020384 cites W2031365833 @default.
• W2357020384 cites W2038068686 @default.
• W2357020384 cites W2053981335 @default.
• W2357020384 cites W2054932751 @default.
• W2357020384 cites W2066588899 @default.
• W2357020384 cites W2066908024 @default.
• W2357020384 cites W2069380387 @default.
• W2357020384 cites W2073207929 @default.
• W2357020384 cites W2074418064 @default.
• W2357020384 cites W2082162228 @default.
• W2357020384 cites W2083922168 @default.
• W2357020384 cites W2091083791 @default.
• W2357020384 cites W2092558048 @default.
• W2357020384 cites W2094625341 @default.
• W2357020384 cites W2094870141 @default.
• W2357020384 cites W2095986103 @default.
• W2357020384 cites W2097593915 @default.
• W2357020384 cites W2101134619 @default.
• W2357020384 cites W2101285661 @default.
• W2357020384 cites W2106129787 @default.
• W2357020384 cites W2112430920 @default.
• W2357020384 cites W2117441254 @default.
• W2357020384 cites W2117460748 @default.
• W2357020384 cites W2117511763 @default.
• W2357020384 cites W2120659572 @default.
• W2357020384 cites W2122904975 @default.
• W2357020384 cites W2123161437 @default.
• W2357020384 cites W2131476866 @default.
• W2357020384 cites W2134697866 @default.
• W2357020384 cites W2146213451 @default.
• W2357020384 cites W2147437793 @default.
• W2357020384 cites W2155975882 @default.
• W2357020384 cites W2164011896 @default.
• W2357020384 cites W2165911471 @default.
• W2357020384 cites W2168242827 @default.
• W2357020384 cites W2325653297 @default.
• W2357020384 cites W2330065815 @default.
• W2357020384 cites W2477231793 @default.
• W2357020384 cites W2513382730 @default.
• W2357020384 cites W4231096603 @default.
• W2357020384 cites W82069182 @default.
• W2357020384 doi "https://doi.org/10.1002/pros.23196" @default.
• W2357020384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27197649" @default.
• W2357020384 hasPublicationYear "2016" @default.
• W2357020384 type Work @default.
• W2357020384 sameAs 2357020384 @default.
• W2357020384 citedByCount "42" @default.
• W2357020384 countsByYear W23570203842016 @default.
• W2357020384 countsByYear W23570203842017 @default.
• W2357020384 countsByYear W23570203842018 @default.
• W2357020384 countsByYear W23570203842019 @default.
• W2357020384 countsByYear W23570203842020 @default.
• W2357020384 countsByYear W23570203842021 @default.
• W2357020384 countsByYear W23570203842022 @default.
• W2357020384 countsByYear W23570203842023 @default.
• W2357020384 crossrefType "journal-article" @default.
• W2357020384 hasAuthorship W2357020384A5019946418 @default.
• W2357020384 hasAuthorship W2357020384A5020692060 @default.
• W2357020384 hasAuthorship W2357020384A5038994606 @default.
• W2357020384 hasAuthorship W2357020384A5043512230 @default.
• W2357020384 hasAuthorship W2357020384A5058385398 @default.
• W2357020384 hasAuthorship W2357020384A5069112511 @default.
• W2357020384 hasAuthorship W2357020384A5077482056 @default.
• W2357020384 hasAuthorship W2357020384A5089478129 @default.
• W2357020384 hasConcept C121608353 @default.
• W2357020384 hasConcept C126322002 @default.
• W2357020384 hasConcept C126838900 @default.
• W2357020384 hasConcept C143409427 @default.
• W2357020384 hasConcept C2775862295 @default.
• W2357020384 hasConcept C2776235491 @default.
• W2357020384 hasConcept C2779013556 @default.
• W2357020384 hasConcept C2780192828 @default.
• W2357020384 hasConcept C2780849966 @default.

• next